Synonym
Fc gamma RIV, CD16-2, Fcgr4
Source
Mouse CD16-2, His Tag (FC4-M52H3) is expressed from human 293 cells (HEK293). It contains AA Gly 21 - Gln 203 (Accession # A0A0B4J1G0-1).
Predicted N-terminus: Gly 21
Request for sequence
Molecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.8 kDa. The protein migrates as 30-38 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
Background
FcgR4(Low affinity immunoglobulin gamma Fc region receptor IV) is also known as CD16-2, FcgammaRIV, receptor for the Fc region of immunoglobulin gamma . Also acts as a receptor for the Fc region of immunoglobulin epsilon . Binds with intermediate affinity to both IgG2a and IgG2b . Does not display binding to IgG1 or IgG3. Plays a role in promoting bone resorption by enhancing osteoclast differentiation following binding to IgG2a. Binds with low affinity to both the a and b allotypes of IgE. Has also been shown to bind to IgE allotype a only but not to allotype b. Binding to IgE promotes macrophage-mediated phagocytosis, antigen presentation to T cells, production of proinflammatory cytokines and the late phase of cutaneous allergic reactions